Apellis logo.jpg
Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
December 02, 2018 12:01 ET | Apellis Pharmaceuticals, Inc.
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...
Apellis logo.jpg
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
November 13, 2018 08:00 ET | Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis...
Apellis logo.jpg
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 07, 2018 16:30 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
November 01, 2018 10:50 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
September 04, 2018 07:30 ET | Apellis Pharmaceuticals, Inc.
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 04, 2018 ...
Apellis logo.jpg
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
June 26, 2018 17:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 26, 2018 07:30 ET | Apellis Pharmaceuticals, Inc.
Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy Treatment-naïve patients with PNH show clinically...
Mean LDH
Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
April 16, 2018 09:23 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Achillion-Logo-150 (4).jpg
CORRECTION - Achillion Pharmaceuticals, Inc.
December 20, 2017 12:12 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
Achillion-Logo-150 (4).jpg
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
December 20, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...